FindTrial
Sign In

Elranatamab (PF-06863135)

DRUG5 trials

Sponsors

Pfizer, PETHEMA Foundation, Massachusetts General Hospital

Conditions

Multiple MyelomaMultiple Myeloma in RelapseNewly Diagnosed Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed or Refractory Multiple MyelomaTransplant Ineligible

Phase 1

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
CompletedNCT04798586
PfizerRelapsed or Refractory Multiple Myeloma
Start: 2021-03-22End: 2023-05-17Updated: 2024-09-27

Phase 2

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Active, not recruitingNCT04649359
PfizerMultiple Myeloma
Start: 2021-02-02End: 2026-12-31Updated: 2025-12-02
Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
RecruitingNCT06282978
PETHEMA FoundationMultiple Myeloma in Relapse
Start: 2023-11-23End: 2029-12-31Target: 50Updated: 2024-03-06
ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
Not yet recruitingNCT07247097
Massachusetts General HospitalMultiple Myeloma, Newly Diagnosed Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM) +1
Start: 2026-04-15End: 2035-12-01Target: 160Updated: 2025-11-25

Unknown Phase

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma
NCT05462639
PfizerMultiple Myeloma
Updated: 2024-08-09

Related Papers

Elranatamab Exposure-Safety Analysis in Relapsed or Refractory Multiple Myeloma.
2026-01-01
Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens
Blood2025-11-03
Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial
Blood2025-11-03
Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study
Blood2025-11-03
Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3
Blood2025-11-03
A population-based gap analysis of bispecific antibody trial access: Racial, geographic, and Medicaid-linked disparities in lymphoma and myeloma
Blood2025-11-03
Elranatamab real-world step-up dosing patterns in relapsed-refractory multiple myeloma patients: Interim analysis Results of the AMbreLA study
Blood2025-11-03
Quantitative clinical pharmacology analysis to support the dose escalation of elranatamab + nirogacestat in the MagnetisMM-4 study
Blood2025-11-03
Comparison of Patient-Reported Peripheral Neuropathy Among Patients Treated With Elranatamab Versus Real-World Clinical Practice in Triple-Class Refractory Multiple Myeloma
JCO oncology advances.2025-10-01
Elranatamab Fixed Dosing: A Safe, Effective, and Convenient Dosing Approach.
2025-08-19
Population Exposure–Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma
Targeted Oncology2025-08-182 citations
Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States.
2025-06-14
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma.
2025-06-05
Efficacy and safety of less frequent dosing with elranatamab (ELRA) in patients with relapsed or refractory multiple myeloma (RRMM): A US subgroup analysis from MagnetisMM-3.
Journal of Clinical Oncology2025-05-28
Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results.
2025-05-14
Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison
Journal of Comparative Effectiveness Research2025-04-071 citations
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma
Targeted Oncology2025-02-252 citations
MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma
Blood2024-11-0514 citations
Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)
Blood2024-11-056 citations
Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma
Blood2024-11-051 citations

45 more papers not shown